# OnCo record paper-tejpar-tumour-location-crystal-fire3-jama-oncol-2017 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-tejpar-tumour-location-crystal-fire3-jama-oncol-2017/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-tejpar-tumour-location-crystal-fire3-jama-oncol-2017" ;
  schema:name "Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials"@en ;
  schema:description "Two European randomised trials, analysed separately, each showed the same thing: cetuximab helps left-sided bowel cancers with no RAS mutation and adds little on the right."@en ;
  schema:url <https://onco.cc/key-papers/paper-tejpar-tumour-location-crystal-fire3-jama-oncol-2017/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1001/jamaoncol.2016.3797>, <https://pubmed.ncbi.nlm.nih.gov/27722750/> ;
  schema:sameAs <https://doi.org/10.1001/jamaoncol.2016.3797> ;
  schema:datePublished "2017"^^xsd:gYear ;
  schema:author "Tejpar S, Stintzing S, Ciardiello F, et al." ;
  onco:cancers <https://onco.cc/cancers/colorectal/> ;
  onco:targets <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/kras/>, <https://onco.cc/targets/braf/> ;
  onco:drugs <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/bevacizumab/> ;
  onco:terms <https://onco.cc/terms/sidedness/>, <https://onco.cc/terms/wild-type/> ;
  onco:trials <https://onco.cc/trials/crystal-fire3/> ;
  onco:people <https://onco.cc/people/eric-van-cutsem/>, <https://onco.cc/people/volker-heinemann/>, <https://onco.cc/people/heinz-josef-lenz/> ;
  onco:journals <https://onco.cc/journals/jama-oncology/> .